Monday , September 25 2017
Home / 2017 / May

Monthly Archives: May 2017

Baxter and Mayo Collaborate to Transform Patient Care

DEERFIELD, Ill. & JACKSONVILLE, Fla.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global medical products company, and Mayo Clinic today announced a new research and development collaboration to advance innovation across a spectrum of therapeutic areas where there are high unmet patient needs. The collaboration agreement will bring together the clinical and …

Read More »

Lilly’s Cyramza Meets Primary Endpoint in Late-Stage Urothelial Cancer Trial

INDIANAPOLIS, May 31, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RANGE study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement. The Phase 3 global, randomized, double-blinded, placebo-controlled trial is evaluating ramucirumab in combination with …

Read More »

Albertsons Expands Specialty Services through Acquisition of MedCart Specialty Pharmacy

BOISE, Idaho, May 31, 2017 /PRNewswire/ — Albertsons Companies announced today that it recently acquired MedCart Specialty Pharmacy in order to strengthen and extend its pharmacy specialty services. MedCart Specialty Pharmacy is an industry-leading, URAC accredited, pharmaceutical and healthcare provider of customized specialty care services and medication management for patients …

Read More »

FDA Grants Breakthrough Therapy Designation to Alnylam’s Acute Hepatic Porphyria Drug

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for givosiran (ALN-AS1), an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the prophylaxis of attacks in patients with acute hepatic porphyria (AHP). …

Read More »

ImmunoGen and Sanofi Amend License Agreements Covering All Sanofi Compounds Using ImmunoGen’s Technology

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company and an affiliate of Sanofi have amended their license agreements covering all compounds in development by Sanofi using ImmunoGen’s technology. Under the terms of …

Read More »

Janssen Enters Deal for Protagonist Therapeutics’ Inflammatory Bowel Disease Candidate

Horsham, Pa., May 30, 2017 ― Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today it has entered into a worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. (Protagonist) to develop, manufacture and commercialize PTG-200, a first-in-class, oral interleukin-23 receptor (IL-23R) antagonist …

Read More »

Gilead’s Investigational HIV Combo Meets Primary Endpoint in Four Late-Stage Studies

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq:GILD) today announced that four Phase 3 studies evaluating a fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) for the treatment of HIV-1 infection met their primary objectives of non-inferiority. Three of the …

Read More »

FDA Grants Priority Review to Kite Pharma’s Non-Hodgkin Lymphoma Drug

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for axicabtagene ciloleucel. The submission follows positive data demonstrated with a single infusion of axicabtagene ciloleucel in the …

Read More »

Novartis’ Zykadia Granted Expanded Approval for First-Line Treatment of ALK-Positive NSCLC

Basel, May 26, 2017 – Novartis today announced the US Food and Drug Administration (FDA) approved the expanded use of Zykadia® (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. Zykadia …

Read More »

GW Pharma’s Epidiolex Reduces Seizures in Children with Dravet Syndrome

London, UK, May 24, 2017 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine …

Read More »